Glenmark Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals' board, at its meeting on August 14, 2025, approved multiple items. First, it approved transferring its Consumer Care business to a newly incorporated wholly owned subsidiary, Glenmark Consumer Care Limited, at a consideration of about INR 240.40 crore, expected to complete by December 31, 2025. The Consumer Care business contributed INR 514.7 crore in turnover (5.6% of standalone) and INR 249.2 crore in net worth (1%) for FY25. Second, the board appointed Ms. Patricia Andrews as a Non-Executive Independent Director for a 5-year term; she is an experienced CEO and pharma/biotech director from the US. Third, Walker Chandiok & Co. LLP was appointed as Statutory Auditor and Rauthan & Associates LLP as Secretarial Auditor, both for 5-year terms. The 47th AGM is scheduled for September 26, 2025.
The Consumer Care hiving off into a focused subsidiary could unlock value and provide sharper strategic focus for that fast-growing segment, though it is a small part of overall business. The appointment of an experienced global pharma independent director strengthens board oversight. These are routine governance and restructuring moves with no immediate material impact on existing shareholders.